VIRADAPT

VIRADAPT

AIDS A French study of AIDS Pts unresponsive to protease inhibitors. See Genotype testing.
Mentioned in ?
References in periodicals archive ?
Drug resistance genotyping in HIV-1 therapy: the VIRADAPT randomized controlled trial.
Drug-resistance genotyping in HIV 1 therapy: the VIRADAPT randomised controlled trial.
The VIRADAPT study was a prospective, open, randomized, and controlled study of individuals with HIV-1 infection for whom combination therapy failed (9).
Economic evaluation of drug resistance genotyping for the adaptation of treatment in HIV-infected patients in the VIRADAPT study.
Patients not in the control arm exhibited substantial improvements after receiving treatment based on the results from genotyping using VIRADAPT.
They examined 34 patients in the VIRADAPT study who were treated with ritonavir (100 mg twice daily) and soft gel saquinavir (600 mg three times daily) as part of a rescue (salvage) regimen.
These data are consistent with results from previous studies such as GART, VIRADAPT, and the HAVANA study.
GART, VIRADAPT, NARVAL and now the HAVANA study show the strong clinical utility of HIV genotyping," said Richard T.
A number of randomized clinical trials including GART, VIRADAPT and NARVAL, have demonstrated improved patient care through use of HIV drug resistance testing using genotyping.
The prospective studies, VIRADAPT and GART, reported last year, showed a significantly greater decrease in HIV viral load by using HIV genotyping, over standard of care, to assist in HIV drug selection.
Guidelines Reference GART and VIRADAPT Studies in Supporting
The SEARCH design is similar to the VGI sponsored French VIRADAPT study that showed a significant reduction in viral load in the group where genotype results were used to guide treatment decisions (3).